Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18277713 | 1.00 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL5287291 | 0.83 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL28362981 | 0.83 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL28366694 | 0.83 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL28362941 | 0.83 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL21176781 | 0.83 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL22303091 | 0.81 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL22303821 | 0.81 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL22339025 | 0.81 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| SCHEMBL1913843 | 0.81 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-13 | — | — | US | disclosed |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | disclosed |
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | THE UNIVERSITY OF MONTANA (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | GOT2, GOT1, OTC | SLC1A3 292/4885SLC1A2 350/4885SLC1A1 310/4885 |
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | SLC1A1, SLC1A3, SLC1A2 | SLC1A3 2/4885SLC1A2 3/4885SLC1A1 1/4885 |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | GOT2, GOT1, OTC | SLC1A3 292/4885SLC1A2 350/4885SLC1A1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.